| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03036449 |
| P698 | PubMed publication ID | 15897154 |
| P50 | author | Vernice Jackson-Lewis | Q67189596 |
| P2093 | author name string | Smeyne RJ | |
| P2860 | cites work | Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology | Q28142758 |
| Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure | Q28145614 | ||
| Peroxynitrite reactions and formation in mitochondria | Q28610681 | ||
| NADPH oxidase: an update | Q28611494 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| Superoxide radical and superoxide dismutases | Q29614204 | ||
| Etiology and pathogenesis of Parkinson's disease | Q33593402 | ||
| Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia | Q33594089 | ||
| Levodopa prolongs life expectancy and is non-toxic to substantia nigra | Q34086050 | ||
| The protective role of levodopa in the human substantia nigra. | Q34091011 | ||
| Changes in cytokines and neurotrophins in Parkinson's disease | Q34155171 | ||
| Mitochondria, oxidative damage, and inflammation in Parkinson's disease | Q34212155 | ||
| Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. | Q64856368 | ||
| Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. | Q67403760 | ||
| Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain | Q68098239 | ||
| Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+ | Q68821467 | ||
| Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease | Q69356679 | ||
| Astrocytes as a primary locus for the conversion MPTP into MPP+ | Q69737655 | ||
| Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q70951248 | ||
| 6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death | Q71799443 | ||
| Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine | Q72059888 | ||
| Peroxynitrite-mediated oxidative protein modifications | Q72257512 | ||
| Enzymatic oxidation of dopamine: the role of prostaglandin H synthase | Q72429983 | ||
| Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment | Q73634982 | ||
| Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo | Q73760293 | ||
| Multiple sclerosis | Q79880889 | ||
| ??? | Q64763419 | ||
| ??? | Q64764121 | ||
| ??? | Q64788284 | ||
| Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration | Q34983386 | ||
| NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease | Q35022998 | ||
| Pathogenic role of glial cells in Parkinson's disease. | Q35050071 | ||
| Neuroinflammatory processes in Parkinson's disease. | Q35094887 | ||
| The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease | Q35171029 | ||
| Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases | Q35564763 | ||
| Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases | Q35617408 | ||
| The oxidant stress hypothesis in Parkinson's disease: evidence supporting it | Q35626743 | ||
| Genetic clues to the pathogenesis of Parkinson's disease | Q35844782 | ||
| Linkage between the proteasome pathway and neurodegenerative diseases and aging | Q35913897 | ||
| Features of the dopaminergic neurotoxin MPTP. | Q36349469 | ||
| Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). | Q36503887 | ||
| Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity | Q37597604 | ||
| Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity | Q37683630 | ||
| Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones | Q39615110 | ||
| Astroglial neurotrophic and neurite-promoting factors | Q40506347 | ||
| Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron | Q40592358 | ||
| Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain | Q40796017 | ||
| Cytotoxicity of microglia | Q40870381 | ||
| A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy | Q40980458 | ||
| Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. | Q41067625 | ||
| MPTP, MPP+ and mitochondrial function | Q41382377 | ||
| Mitochondrial complex I deficiency in Parkinson's disease | Q41821730 | ||
| Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes | Q41940311 | ||
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes | Q42437029 | ||
| Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. | Q42468902 | ||
| Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. | Q44226809 | ||
| Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function | Q44292891 | ||
| Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. | Q44535784 | ||
| Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin | Q44570583 | ||
| 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis | Q44616102 | ||
| Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study | Q44794339 | ||
| Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway | Q44870587 | ||
| Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). | Q45111221 | ||
| Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity | Q46070812 | ||
| Developmental neurobiology. The milieu is the message | Q48088776 | ||
| Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease | Q48132256 | ||
| Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography | Q48132783 | ||
| Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. | Q48223155 | ||
| FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. | Q48230911 | ||
| Manganese superoxide dismutase overexpression attenuates MPTP toxicity. | Q48332030 | ||
| Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine | Q48477579 | ||
| Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. | Q48631699 | ||
| In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine | Q48633831 | ||
| The parkinsonian toxin MPTP: action and mechanism. | Q51679376 | ||
| Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. | Q53216133 | ||
| Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease | Q56567926 | ||
| Genetic contributions to Parkinson's disease | Q59544643 | ||
| P433 | issue | 3 | |
| P921 | main subject | neurotoxicity | Q3338704 |
| P304 | page(s) | 193-202 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Neurotoxicity Research | Q15764278 |
| P1476 | title | MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview | |
| P478 | volume | 7 |
| Q39266481 | A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway |
| Q51786227 | A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. |
| Q36481770 | A tiered approach to life stages testing for agricultural chemical safety assessment |
| Q37239705 | Ampelopsis Radix Protects Dopaminergic Neurons against 1-Methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Toxicity in Parkinson's Disease Models In Vitro and In Vivo |
| Q35172603 | Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure |
| Q39819662 | Commitment of 1-methyl-4-phenylpyrinidinium ion-induced neuronal cell death by proteasome-mediated degradation of p35 cyclin-dependent kinase 5 activator |
| Q35081800 | Dietary administration of paraquat for 13 weeks does not result in a loss of dopaminergic neurons in the substantia nigra of C57BL/6J mice |
| Q37076753 | Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum |
| Q55308535 | Dual modulation on glial cells by tetrahydroxystilbene glucoside protects against dopamine neuronal loss. |
| Q58799110 | Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse |
| Q48492782 | Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease |
| Q80975514 | Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats |
| Q43748635 | Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine |
| Q35915111 | HIF1α is necessary for exercise-induced neuroprotection while HIF2α is needed for dopaminergic neuron survival in the substantia nigra pars compacta |
| Q41262976 | Immune responses in Parkinson's disease: interplay between central and peripheral immune systems |
| Q38425458 | Inflammation in Parkinson's disease: role of glucocorticoids. |
| Q28577454 | Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity |
| Q34217427 | Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice |
| Q46567817 | Microglial cells and Parkinson's disease |
| Q36085162 | Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. |
| Q36696105 | Neurotoxins and neurotoxicity mechanisms. An overview. |
| Q38108307 | Nitric oxide donors as neuroprotective agents after an ischemic stroke-related inflammatory reaction |
| Q26798897 | Oxidative stress and Parkinson's disease |
| Q35876266 | Oxidative stress and microglial cells in Parkinson's disease |
| Q34068032 | Particulate matter neurotoxicity in culture is size-dependent |
| Q37341777 | Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia |
| Q33687436 | Potential future neuroprotective therapies for neurodegenerative disorders and stroke |
| Q92622174 | Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease |
| Q26750630 | Redox Imbalance and Viral Infections in Neurodegenerative Diseases |
| Q92277505 | Renal Dopamine Oxidation and Inflammation in High Salt Fed Rats |
| Q46465276 | Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson's disease. |
| Q36119968 | Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. |
| Q37208507 | Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia |
| Q39975768 | The catecholaminergic RCSN-3 cell line: a model to study dopamine metabolism |
| Q35119950 | The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons |
| Q47135899 | α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin. |
Search more.